171 related articles for article (PubMed ID: 8418237)
1. Intensive preoperative chemotherapy with colony-stimulating factor for resectable adenocarcinoma of the esophagus or gastroesophageal junction.
Ajani JA; Roth JA; Ryan MB; Putnam JB; Pazdur R; Levin B; Gutterman JU; McMurtrey M
J Clin Oncol; 1993 Jan; 11(1):22-8. PubMed ID: 8418237
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction.
Ajani JA; Roth JA; Ryan B; McMurtrey M; Rich TA; Jackson DE; Abbruzzese JL; Levin B; DeCaro L; Mountain C
J Clin Oncol; 1990 Jul; 8(7):1231-8. PubMed ID: 2358838
[TBL] [Abstract][Full Text] [Related]
3. Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma.
Ajani JA; Mayer RJ; Ota DM; Steele GD; Evans D; Roh M; Sugarbaker DJ; Dumas P; Gray C; Vena DA
J Natl Cancer Inst; 1993 Nov; 85(22):1839-44. PubMed ID: 8230264
[TBL] [Abstract][Full Text] [Related]
4. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction.
Ajani JA; Komaki R; Putnam JB; Walsh G; Nesbitt J; Pisters PW; Lynch PM; Vaporciyan A; Smythe R; Lahoti S; Raijman I; Swisher S; Martin FD; Roth JA
Cancer; 2001 Jul; 92(2):279-86. PubMed ID: 11466680
[TBL] [Abstract][Full Text] [Related]
5. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction.
Ajani JA; Walsh G; Komaki R; Morris J; Swisher SG; Putnam JB; Lynch PM; Wu TT; Smythe R; Vaporciyan A; Faust J; Cohen DS; Nivers R; Roth JA
Cancer; 2004 Jun; 100(11):2347-54. PubMed ID: 15160337
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
[TBL] [Abstract][Full Text] [Related]
7. Safety, efficacy, and long-term follow-up evaluation of perioperative epirubicin, Cisplatin, and capecitabine chemotherapy in esophageal resection for adenocarcinoma.
van der Sluis PC; Ubink I; van der Horst S; Boonstra JJ; Voest EE; Ruurda JP; Borel Rinkes IH; Wiezer MJ; Schipper ME; Siersema PD; Los M; Lolkema MP; van Hillegersberg R
Ann Surg Oncol; 2015 May; 22(5):1555-63. PubMed ID: 25564156
[TBL] [Abstract][Full Text] [Related]
8. Effective radiochemotherapy with cisplatin and etoposide for the management of patients with locally inoperable and metastatic esophageal carcinoma.
Hejna M; Kornek GV; Schratter-Sehn AU; Zach M; Schoder M; Raderer M; Rosen H; Schiessel R; Scheithauer W
Cancer; 1996 Oct; 78(8):1646-50. PubMed ID: 8859175
[TBL] [Abstract][Full Text] [Related]
9. Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer.
Jary M; Ghiringhelli F; Jacquin M; Fein F; Nguyen T; Cleau D; Nerich V; El Gani M; Mathieu P; Valmary-Degano S; Arnould L; Lassabe C; Lamfichekh N; Fratté S; Paget-Bailly S; Bonnetain F; Borg C; Kim S
Cancer Chemother Pharmacol; 2014 Jul; 74(1):141-50. PubMed ID: 24824852
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
[TBL] [Abstract][Full Text] [Related]
11. Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level.
Vadhan-Raj S; Broxmeyer HE; Hittelman WN; Papadopoulos NE; Chawla SP; Fenoglio C; Cooper S; Buescher ES; Frenck RW; Holian A
J Clin Oncol; 1992 Aug; 10(8):1266-77. PubMed ID: 1634916
[TBL] [Abstract][Full Text] [Related]
12. Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Steward WP; Verweij J; Somers R; Spooner D; Kerbrat P; Clavel M; Crowther D; Rouesse J; Tursz T; Tueni E
J Clin Oncol; 1993 Jan; 11(1):15-21. PubMed ID: 8418226
[TBL] [Abstract][Full Text] [Related]
13. Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus.
Heath EI; Burtness BA; Heitmiller RF; Salem R; Kleinberg L; Knisely JP; Yang SC; Talamini MA; Kaufman HS; Canto MI; Topazian M; Wu TT; Olukayode K; Forastiere AA
J Clin Oncol; 2000 Feb; 18(4):868-76. PubMed ID: 10673530
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant (cisplatin, etoposide, and 5-fluorouracil) chemotherapy after curative resection of gastric adenocarcinomas involving the esophagogastric junction.
Ryoo BY; Kang YK; Im YH; Kim YJ; Kim BS; Kim TY; Jung SH; Park JH; Baek HJ; Kim YC; Shim YM; Kim CM; Zo JI
Am J Clin Oncol; 1999 Jun; 22(3):253-7. PubMed ID: 10362331
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of five courses of pre-operative chemotherapy in patients with resectable adenocarcinoma of the oesophagus or gastrooesophageal junction.
Ajani JA; Roth JA; Putnam JB; Walsh G; Lynch PM; Roubein LD; Ryan MB; Natrajan G; Gould P
Eur J Cancer; 1995; 31A(5):665-70. PubMed ID: 7640036
[TBL] [Abstract][Full Text] [Related]
16. Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric adenocarcinoma: results of a phase II trial.
Lerner A; Gonin R; Steele GD; Mayer RJ
J Clin Oncol; 1992 Apr; 10(4):536-40. PubMed ID: 1548518
[TBL] [Abstract][Full Text] [Related]
17. Adenocarcinoma of the esophagus and gastroesophageal junction. Clinical and pathologic assessment of response to induction chemotherapy.
Adelstein DJ; Rice TW; Boyce GA; Sivak MV; Van Kirk MA; Kirby TJ; van Stolk RU; Bukowski RM
Am J Clin Oncol; 1994 Feb; 17(1):14-8. PubMed ID: 8311001
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of etoposide, doxorubicin and cisplatin (EAP) in combination with GM-CSF.
Ford PA; Arbuck SG; Minniti C; Miller LL; DeMaria D; O'Dwyer PJ
Eur J Cancer; 1996 Apr; 32A(4):631-5. PubMed ID: 8695266
[TBL] [Abstract][Full Text] [Related]
19. Combined paclitaxel, cisplatin, and etoposide for patients with previously untreated esophageal and gastroesophageal carcinomas.
Lokich JJ; Sonneborn H; Anderson NR; Bern MM; Coco FV; Dow E; Oliynyk P
Cancer; 1999 Jun; 85(11):2347-51. PubMed ID: 10357404
[TBL] [Abstract][Full Text] [Related]
20. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial.
Loehrer PJ; Elson P; Dreicer R; Hahn R; Nichols CR; Williams R; Einhorn LH
J Clin Oncol; 1994 Mar; 12(3):483-8. PubMed ID: 7509853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]